B+
Bull case
25%
Probability
Target price
$1,020.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
MCK
McKessonBNYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
The company-specific follow-up remains constructive: Q1 adjusted EPS grew 20%, revenue grew 8%, specialty and oncology-related businesses provided operating momentum, and FY27 adjusted EPS guidance was raised. Buybacks and a higher dividend add shareholder-return support.
Posture
Constructive
Lead driver
Value
What changed
News driver: McKesson and CD&R strike $5.8bn deal to buy infusion services provider.
What can break
Execution, financing, timing, and valuation risk around the planned Medical-Surgical Solutions separation.
Momentum
89
Value
60
Sentiment
45
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $940.00 · Bull $1,020.00 · Bear $790.00Analysis 2026-08-08; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-26 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-26
Investment thesis
As of 2026-10-26
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-26. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $1,021.64
Why
Momentum89 · Δ7d +5.2
Value60 · Δ7d +0.7
Sentiment45 · Δ7d -1.0
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • News driver: McKesson and CD&R strike $5.8bn deal to buy infusion services provider.
- • Value remains the lead driver in the composite, 7D delta +0.7.
Contradictions & invalidation
- • Execution, financing, timing, and valuation risk around the planned Medical-Surgical Solutions separation.
- • Lower branded-pharmaceutical contributions and potential volatility from segment mix.
- • GAAP EPS declined 18% year over year because of a redemption-value adjustment, operating cash flow was negative $220 million and free cash flow was negative $372 million in Q1, while lower branded-pharmaceutical contributions and execution risk around the planned separation remain offsets.
Catalyst clock
2026-08-05
Specialty and oncology operating momentum
Lead driver: Value · See fundamentals
Momentum
89
8% active weight
Current posture
7d trendFlat
Δ7d
+5.2
Δ21d
+16.8
Value
60
47% active weight
Current posture
7d trendFlat
Δ7d
+0.7
Δ21d
-0.8
Sentiment
45
45% active weight
Current posture
7d trendSoftening
Δ7d
-1.0
Δ21d
-20.4
Why this grade
Composite grade B. Momentum 88.7 / Value 59.6 / Sentiment 44.8
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-08. Scenario method
Most likely
B
Base case
55%
Probability
Target price
$940.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$790.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$116.68B
Beta
0.41
Shares Out
116.59M
P/E (TTM)
25.7
P/S (TTM)
0.26
P/FCF (TTM)
17.99
Rev YoY
+7.7%
EPS YoY
-17.5%
Gross Margin
+3.4%
Op Margin
+1.6%
Net Debt
$4.55B
Current Ratio
0.89
As of 2026-10-26 • Updated nightlySource: Internal modelMethods & Data